Author(s): Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, , Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, , Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, , Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T,
Abstract Share this page
Abstract Preeclampsia is a pregnancy-specific hypertensive syndrome that causes substantial maternal and fetal morbidity and mortality. Maternal endothelial dysfunction mediated by excess placenta-derived soluble VEGF receptor 1 (sVEGFR1 or sFlt1) is emerging as a prominent component in disease pathogenesis. We report a novel placenta-derived soluble TGF-beta coreceptor, endoglin (sEng), which is elevated in the sera of preeclamptic individuals, correlates with disease severity and falls after delivery. sEng inhibits formation of capillary tubes in vitro and induces vascular permeability and hypertension in vivo. Its effects in pregnant rats are amplified by coadministration of sFlt1, leading to severe preeclampsia including the HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome and restriction of fetal growth. sEng impairs binding of TGF-beta1 to its receptors and downstream signaling including effects on activation of eNOS and vasodilation, suggesting that sEng leads to dysregulated TGF-beta signaling in the vasculature. Our results suggest that sEng may act in concert with sFlt1 to induce severe preeclampsia.
This article was published in Nat Med
and referenced in Immunotherapy: Open Access